A 40 year-old man with hairy cell leukemia (HCL) was treated with Cladribin, but achieved only partial response (PR). As expected, both 2 and 5 years later the disease had progressed and the patient was therefore twice retreated with Cladribin. A bone marrow examination after the last Cladribin course showed complete response with residual disease (CR-RD). The patient received consolidation therapy with Rituximab, achieved complete response (CR) and was still in CR 9 months later. Rituximab is a good treatment option for patients with refractory HCL because of its significant activity and minimal toxicity.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
hairy cell
8
complete response
8
[complete remission
4
remission rituximab
4
rituximab treatment
4
treatment refractory
4
refractory hairy
4
cell leukemia]
4
leukemia] year-old
4
year-old man
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!